{
    "root": "5d5aaac9-95da-4d88-817b-bca1c40739c9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Premarin",
    "value": "20250506",
    "ingredients": [
        {
            "name": "ESTROGENS, CONJUGATED",
            "code": "IU5QR144QX"
        },
        {
            "name": "TRIBASIC CALCIUM PHOSPHATE",
            "code": "91D9GV0Z28",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POWDERED CELLULOSE",
            "code": "SMD1X3XO9M"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "CARNAUBA WAX",
            "code": "R12CBM0EIZ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_73702"
        },
        {
            "name": "HYPROMELLOSE 2208 (15000 MPA.S)",
            "code": "Z78RG6M2N2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "D&C RED NO. 30",
            "code": "2S42T2808B"
        },
        {
            "name": "D&C RED NO. 7",
            "code": "ECW0LZ41X8"
        }
    ],
    "indications": {
        "text": "premarin mixture estrogens indicated : \u2022 treatment moderate severe vasomotor symptoms due menopause ( 1.1 ) \u2022 treatment moderate severe vulvar vaginal atrophy due menopause ( 1.2 ) \u2022 treatment hypoestrogenism due hypogonadism , castration primary ovarian failure ( 1.3 ) \u2022 treatment breast cancer ( palliation ) appropriately selected women men metastatic disease ( 1.4 ) \u2022 treatment advanced androgen-dependent carcinoma prostate ( palliation ) ( 1.5 ) \u2022 prevention postmenopausal osteoporosis ( 1.6 )",
        "doid_entities": [
            {
                "text": "hypogonadism (DOID:1924)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1924"
            },
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "carcinoma (DOID:305)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_305"
            },
            {
                "text": "osteoporosis (DOID:11476)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11476"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe vulvar vaginal",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_180312"
            }
        ]
    },
    "contraindications": {
        "text": "generally , estrogen therapy prescribed postmenopausal woman uterus , progestin considered reduce risk endometrial cancer [ boxed warning ] . woman without uterus need progestin . cases , however , hysterectomized women history endometriosis may need progestin [ ( 5.2 , 5.16 ) ] . estrogen-alone , combination progestin , lowest effective dose shortest duration consistent treatment goals risks individual woman . postmenopausal women re-evaluated periodically clinically appropriate determine treatment still necessary . premarin may taken without regard meals .",
        "doid_entities": [
            {
                "text": "endometrial cancer (DOID:1380)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1380"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "endometriosis (DOID:289)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_289"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "premarin therapy contraindicated individuals following conditions : \u2022undiagnosed abnormal genital bleeding [ ( 5.2 ) ] \u2022breast cancer history breast cancer except appropriately selected patients treated metastatic disease [ ( 5.2 ) ] \u2022estrogen-dependent neoplasia [ ( 5.2 ) ] \u2022active dvt , pe , history conditions [ ( 5.1 ) ] \u2022active arterial thromboembolic disease ( example stroke myocardial infarction ) , history conditions [ ( 5.1 ) ] \u2022known anaphylactic reaction angioedema premarin [ ( 5.7 , 5.15 ) ] \u2022hepatic impairment disease [ ( 5.11 ) ] \u2022protein c , protein antithrombin deficiency , known thrombophilic disorders .",
    "indications_original": "PREMARIN is a mixture of estrogens indicated for: \u2022 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) \u2022 Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) \u2022 Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) \u2022 Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 ) \u2022 Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 ) \u2022 Prevention of Postmenopausal Osteoporosis ( 1.6 )",
    "contraindications_original": "Generally, when estrogen therapy is prescribed for a postmenopausal woman with a uterus, a progestin should be considered to reduce the risk of endometrial cancer [see Boxed Warning].\n                  \n                  A woman without a uterus does not need progestin. In some cases, however, hysterectomized women with a history of endometriosis may need a progestin [see Warnings and Precautions (5.2,\n                         5.16)].\n                  Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary. \n                  PREMARIN may be taken without regard to meals.",
    "adverseReactions_original": "PREMARIN therapy is contraindicated in individuals with any of the following conditions: \n                  \n                     \n                        \u2022Undiagnosed abnormal genital bleeding [see Warnings and Precautions (5.2)]\n                     \n                     \n                        \u2022Breast cancer or a history of breast cancer except in appropriately selected patients being treated for metastatic disease [see Warnings and Precautions (5.2)]\n                     \n                     \n                        \u2022Estrogen-dependent neoplasia [see Warnings and Precautions (5.2)]\n                     \n                     \n                        \u2022Active DVT, PE, or a history of these conditions [see Warnings and Precautions (5.1)]\n                     \n                     \n                        \u2022Active arterial thromboembolic disease (for example stroke and MI), or a history of these conditions [see Warnings and Precautions (5.1)]\n                     \n                     \n                        \u2022Known anaphylactic reaction or angioedema with PREMARIN [see Warnings and Precautions (5.7, 5.15)]\n                     \n                     \n                        \u2022Hepatic impairment or disease [see Warnings and Precautions (5.11)]\n                     \n                     \n                        \u2022Protein C, protein S or antithrombin deficiency, or other known thrombophilic disorders.",
    "drug": [
        {
            "name": "Premarin",
            "drugbank_id": "https://go.drugbank.com/drugs/DB12290"
        }
    ]
}